Objective: The aim of this study was to establish a novel rat model of neonatal complications secondary to intra-amniotic infection/inflammation in order to investigate the therapeutic efficacy of rat umbilical cord-derived mesenchymal stem cells (rUCMSCs).
Introduction
Advances in modern neonatal intensive care have resulted in decreased perinatal mortality, although high morbidity rates due to periventricular leukomalacia (PVL) and bronchopulmonary dysplasia (BPD) are still observed 1, 2) .
PVL, which is also referred to as immature cerebral white matter injury, leads to localized necrosis or a decrease in myelination 3, 4) . It causes cerebral palsy and cognitive/ behavioral deficits in neonates 5) . Although ischemia/ reperfusion injury is considered to be either the only or at lease most common cause of PVL, intra-amniotic infection/ inflammation (diagnosed pathologically as chorioamnionitis)
also plays an additional role in its etiology 6, 7) . Intra-amniotic infection/inflammation has been reported to be involved in BPD 8, 9) . BPD interferes with normal lung development processes, such as alveolarization and septation 10) .
Although the normal signals required for alveolarization are not clearly understood, transgenic mice overexpressing cytokines in the lung such as tumor necrosis factor (TNF)
, transforming growth factor (TGF) α 12) and interleukin (IL)-6 13) exhibit problems with alveolarization. However, the etiology of neonatal complications is an intricate process, involving immaturity, fetal distress and postnatal intervention, and exposure of the fetus to intra-amniotic infection/inflammation is an important factor that may greatly impinge upon the general condition of the neonate.
When intra-amniotic infection/inflammation is suspected in pregnant women, physicians have no choice but to deliver the baby prematurely before the inflammation spreads and harms the fetus, regardless of the clinical benefit that might result from prolonging the pregnancy. Physicians often encounter difficulties in diagnosing intra-amniotic infection/ inflammation when the maternal inflammatory response is minor or subclinical. This leaves the fetus exposed to a chronic inflammatory response until delivery, and complications such as PVL or BPD only become apparent postnatally. Currently, no fundamental therapy for PVL or BPD is available.
Postnatal hypoxic-ischemic animal models have often been used as models of PVL. Unilateral carotid artery ligation followed by the exposure of immature animals to hypoxia for a few hours is one such cerebral hypoxia model 14, 15) . Although various inflammation models in which brain injury was induced by the administration of Escherichia coli or lipopolysaccharide (LPS) in the antenatal or postnatal period were also used to study PVL 16) , only a few animal models utilizing the neonatal condition after exposure to chronic intra-amniotic infection/inflammation exist.
Clinically, brain injury commences and then progresses as a consequence of intrauterine infection during the fetal period, with ongoing manifestations during the postnatal period. Additionally, Rees and Inder reported that fetal brain injury is more severe in the presence of maternal inflammation and infection 17) . Hence, to investigate the etiology and to develop a novel therapy as well as prophylaxis for these complications, we established an animal model in which the fetuses are exposed to extended inflammation and investigated the therapeutic efficacy of mesenchymal stem cells (MSCs), which have been reported to be effective in hypoxic-ischemic neonatal rodent models 14, 18) .
MSCs are multi-potent cells with a self-renewal capacity as well as osteogenic, adipogenic, and chondrogenic differentiation in vitro 19) . Their anti-inflammatory, antiapoptotic, angiogenic and immunomodulatory potentials have been reported 20) . These cells can be isolated from almost any adult tissues, including the bone marrow, adipose tissue and teeth. Since the umbilical cord is generally considered "medical waste", MSCs can be abundantly and non-invasively isolated from the umbilical cord (UCMSCs) 21) .
In this study, we successfully generated a rat intraamniotic infection/inflammation model by the administration of a relatively low-dose of LPS into the amniotic cavity.
We also demonstrated that intravenous injection of rat UCMSCs (rUCMSCs) into these neonatal rats attenuated the reduction of myelination and the deficiency in alveolarization.
Materials and methods

1)Animals
This study was approved by the Committee for Animal
Experiments of Tokyo Medical and Dental University (#0130144A). Pregnant Sprague-Dawley (SD) rats were purchased from the Sankyo Labo Service (Tokyo, Japan) on gestational age day (GAD) 14. The gestational period of this animal was 22.5 days. The rats were kept in clean cages with free access to food and water.
2)Intra-amniotic infection model and tissue collection
To develop a rat intra-amniotic infection/inflammation model, we referred to previous studies on preterm births and neonatal complications 15, 22, 23) . On GAD 16, laparotomy under inhalation anesthesia (2% isoflurane in air) was In separate experiments, other rats delivered spontaneously 6 days after LPS administration. The number of live neonates was counted one day after delivery. The alive-birth rate was calculated as follows:
Alive-birth rate = number of live pups on postnatal day (PND) 1/number of live fetuses on GAD 16.
The pups in the experimental group received 20 μL of α minimum essential medium: αMEM) intravenously for the subsequent therapeutic experiment.
3)Tissue preparation
On GAD 20, the rats that were previously injected with LPS or saline were once again anesthetized and laparotomy was performed to collect their placentas. The placentas were separated into two parts. The part that included the umbilical cord insertion site was fixed with 4%
paraformaldehyde (PFA), while the other was placed in RNAlater ® (Life Technologies Japan, Tokyo, Japan) for a week and stored at 80℃ for further experiments. On PND 14, the pups that were born from the experimental and control group animals were anesthetized with Nembutal and perfusion fixation with 4% PFA was performed to harvest the neonatal brains and lungs. The brains and lungs were collected and immersed in 4% PFA at 4℃ for several days.
4)Immunohistochemistry
The placentas, brains and lungs were embedded in min at room temperature. An avidin-biotinylated peroxidase complex detection system was used to enhance sensitivity.
Color development of the sections was performed by using 3,3'-diaminobenzidine (DAB) and nuclear staining was performed with methyl green.
5)Placental immune cell counts
Placental sections containing the umbilical cord insertion site were stained with hematoxylin and eosin (H&E). Five random areas in the labyrinth zone in each placenta were captured using a photomicrograph (x400 magnification, Leica, Wetzlar, Germany). The number of segmented leukocytes in the maternal blood space was blindly counted.
Infiltrated neutrophils were quantified by counting MPOpositive cells.
6)RNA extraction and real-time quantitative polymerase chain reaction (RT-PCR)
Total RNA from the placentas was isolated using ISOGEN (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. The purity and concentration of the extracted RNA were measured by spectrophotometry (Gene Quant pro, GE Healthcare Japan, Tokyo, Japan).
One microgram of total RNA was reverse-transcribed using Institute of Health, Bethesda, MD, USA).
8)Assessment of pulmonary alveolar maturation in neonatal rats
The neonatal lung sections were stained with H&E.
Neonatal lung images were captured under microscopy (Biozero; Keyence Co., Osaka, Japan, x32 magnification) and lung maturation was assessed using the radial alveolar count method (RAC) 24, 25) . Briefly, the number of alveoli on a radial line from the pleura to the nearest terminal bronchiole was counted in five random areas in each section.
9)Isolation and administration of rUCMSCs
rUCMSCs were isolated by using the tissue explant intravenously on postnatal day 1 and 7. Tissue collection and assessment of periventricular white matter damage was performed as described above. 
10)Statistical analysis
Results
On GAD 16, LPS or saline was injected into individual gestational sacs. Preterm delivery was not observed. The alive-birth rate was significantly lower in LPS-injected animals (LPS group) compared with saline-injected animals (control group) (67±4% vs. 89±4% respectively, means± S.E.M. p=0.006) (e.g., Fig. 1A ). The weight of the pups was significantly higher in the LPS group on PND 1 and higher in the control group on PND 14 (e.g., Fig. 1B ).
First, placental inflammation was examined histologically.
A significant increase in inflammatory cell infiltration was observed in the placenta of the LPS-administered animals (LPS group: 3.83±0.28/high power field (hpf) vs. control group 2.38±0.28/hpf, means±S.E.M. p=0.002) (e.g., Fig. 2 A-C). The interstitium of the placental labyrinth zone tended to be thickened in the LPS group. MPO-immunostaining revealed greater MPO-positive cell infiltration in the placenta of the LPS group of animals when compared to the control animals (e.g., Fig. 2 D-F days after administration (e.g. Fig. 2G ). On the other hand, ±4.25% vs. control group: 44.5±5.67%, means±S.E.M.
p<0.01), suggesting a delay or impairment of myelination (e.g., Fig. 3A ,B,G). At 7 days after the administration of rUCMSCs, the MBP-positive area significantly increased in the periventricular region of control rats as compared to that in the LPS group (e.g., Fig. 3 B,C,G) . In the neonatal lungs, a significant reduction of RAC was observed in the LPS group (LPS group: 14.0±0.68/line vs. control group:
9.40±0.95/line, means±S.E.M. p<0.05) (e.g., Fig. 3D ,E,H).
A thicker interstitium was observed in the LPS group, which is a pathognomonic feature of chronic lung disease.
In the LPS+MSC group, RAC was significantly increased (e.g., Fig. 3E,F,H) . These results suggest that rUCMSCs ameliorate both myelination and alveolarization.
Discussion
We demonstrated that LPS administration into the amniotic Mean±SEM, Analysis of variance and Turkey-Kramer tests, *p<0.05
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We found that inflammatory cell infiltration and the expression of the protein markers for chronic inflammation significantly increased in the rat placenta on GAD 20.
Furthermore, a decrease in myelination and alveolarization was found in the rats on PND 14.
In this study, we used LPS, which is wall component of gram negative bacteria. Several reports have demonstrated that intra-amniotic infection with Escherichia coli (E. coli)
leads to preterm-stillbirth in animal models [26] [27] [28] , while the infusion of LPS has been reported to cause both preterm-stillbirth 29) and neonatal injuries without preterm and reactive oxygen species [32] [33] [34] . The clinical relation between BPD and intra-amniotic infection/inflammation has been widely accepted 35, 36) . A few reports have demonstrated the causative mechanism of intra-amniotic infection/inflammation (induced) induces BPD. Benjamin et al. showed that LPS exposure resulted in a decreased expression of fibroblast growth factor-10, a critical protein in bronchial and bronchiolar development 37) . Miller et al. found that prenatal LPS exposure increases the production of angiogenic CC chemokines, such as macrophage inflammatory protein-1α and monocyte chemoattractant protein-1, in the fetal lung, speculating that an inflammationmediated surge in angiogenesis leads to the formation of aberrant alveolar capillaries in the lungs 38) . Further studies are required to investigate whether these mechanisms are involved in the model reported here.
As both the blood circulation and amniotic/alveolar fluid pathways might be involved in the extension of inflammation to the fetus, the dose of LPS used, which was relatively lower than those used in previous reports 15, 23) , was enough to cause the brain and lung injuries in this model.
We showed the therapeutic effect of rUCMSCs on these brain and lung injuries. Therapeutic effects of MSCs have previously been reported for ischemia/hypoxia encephalopathy and hyperoxia-induced lung injury 39, 40) . However, the effect of MSCs on PVL or BPD caused by intra-amniotic infection/inflammation is not wells understood. Surprisingly, 
